全文获取类型
收费全文 | 43997篇 |
免费 | 3512篇 |
国内免费 | 962篇 |
专业分类
耳鼻咽喉 | 268篇 |
儿科学 | 865篇 |
妇产科学 | 1342篇 |
基础医学 | 4075篇 |
口腔科学 | 809篇 |
临床医学 | 4896篇 |
内科学 | 6570篇 |
皮肤病学 | 266篇 |
神经病学 | 1749篇 |
特种医学 | 1605篇 |
外国民族医学 | 9篇 |
外科学 | 3464篇 |
综合类 | 7059篇 |
现状与发展 | 1篇 |
预防医学 | 6792篇 |
眼科学 | 310篇 |
药学 | 4845篇 |
100篇 | |
中国医学 | 1706篇 |
肿瘤学 | 1740篇 |
出版年
2023年 | 579篇 |
2022年 | 908篇 |
2021年 | 1690篇 |
2020年 | 1677篇 |
2019年 | 1444篇 |
2018年 | 1485篇 |
2017年 | 1434篇 |
2016年 | 1527篇 |
2015年 | 1459篇 |
2014年 | 2963篇 |
2013年 | 3074篇 |
2012年 | 2783篇 |
2011年 | 2986篇 |
2010年 | 2245篇 |
2009年 | 2054篇 |
2008年 | 2022篇 |
2007年 | 2148篇 |
2006年 | 1742篇 |
2005年 | 1572篇 |
2004年 | 1348篇 |
2003年 | 1121篇 |
2002年 | 1010篇 |
2001年 | 879篇 |
2000年 | 770篇 |
1999年 | 712篇 |
1998年 | 560篇 |
1997年 | 568篇 |
1996年 | 548篇 |
1995年 | 493篇 |
1994年 | 487篇 |
1993年 | 366篇 |
1992年 | 391篇 |
1991年 | 355篇 |
1990年 | 292篇 |
1989年 | 288篇 |
1988年 | 250篇 |
1987年 | 202篇 |
1986年 | 191篇 |
1985年 | 247篇 |
1984年 | 211篇 |
1983年 | 134篇 |
1982年 | 182篇 |
1981年 | 156篇 |
1980年 | 139篇 |
1979年 | 125篇 |
1978年 | 97篇 |
1977年 | 90篇 |
1976年 | 86篇 |
1975年 | 89篇 |
1974年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
41.
The aim of the present study was to establish survival rates, as well as crestal bone loss (CBL) of narrow diameter implants (NDI), compared to regular diameter implants (RDI). The current review followed the Enhancing the QUAlity and Transparency Of health Research guidelines and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. We searched main databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register) for articles addressing the focused question up to and including May 2018. Meta‐analyses were conducted for CBL and survival rates. Qualitatively, three clinical studies showed comparable CBL and survival rates between NDI and RDI at follow up. Only one study showed increased CBL around NDI compared to RDI. The overall weighted mean difference (WMD) for CBL (WMD = .06, 95% confidence interval [CI] = ‐.38‐.51, P=.76) and risk difference for survival rate (risk difference = .88, 95% CI = .22‐3.50, P=.85) were not significant between the NDI and RDI groups at follow up. NDI and RDI showed comparable CBL and survival rates. However, the findings of the present study should be interpreted with caution due to significant heterogeneity and the low number of included studies. Further randomized, controlled trials should be performed in order to obtain strong conclusions. 相似文献
42.
目的:探讨补脾益肾方联合温针灸治疗对重症肌无力(MG)疗效及对免疫功能的影响。方法:随机分配84例MG病例为西药组和针药组,每组各42例,西药组给予常规西药治疗,即泼尼松片中剂量冲击,小剂量隔日维持治疗,针药组基于以上用药基础给予补脾益肾方联合温针灸治疗,治疗3个月后,统计两组治疗前后的中医证候积分,评估两组中医证候疗效,对比治疗前后的颈部血管流速、T淋巴细胞亚群水平和血清可溶性白细胞介素6受体水平。结果:治疗后,两组中医证候积分显著降低,针药组的变化幅度大于西药组(P<0.05); 针药组的中医证候总有效率低于西药组(P<0.05); 治疗后,两组颈内动脉(ICA)、颈总动脉(CCA)、颈外动脉(ECA)显著提高(P<0.05),两组T淋巴细胞中CD3+、CD4+亚群所占比和CD8+、CD4+比值显著降低(P<0.05),两组血清slL-6R水平均显著降低(P<0.05),以上指标针药组变化幅度大于西药组(P<0.05)。结论:补脾益肾方联合温针灸治疗能缓解MG患者的中医证候症状,提高疗效,促进其颈部血管循环,纠正患者自身机体免疫功能紊乱。 相似文献
43.
《Clinical lung cancer》2020,21(5):e464-e473
BackgroundIn advanced epidermal growth factor receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) patients whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors (TKIs), liquid biopsy (LB) is routinely used to evaluate the presence of EGFR T790M as an acquired resistance mechanism. The objective of this study was to assess a real-life picture of EGFR T790M detection in LB.Materials and MethodsLiquid biopsies performed between June 2016 and October 2018 for advanced EGFR-mutated NSCLC at disease progression during treatment with first- and second-generation TKIs were retrospectively evaluated in 5 Italian centers. Circulating tumor DNA was extracted from plasma and tested with different commercial kits. The detection rate in LBs and the patients’ characteristics were correlated.ResultsWe enrolled 120 consecutive patients. The overall T790M detection rate observed using LB was 25.8%. Fifty-four of 89 (60.7%) patients with negative LB results underwent tissue rebiopsy, and 56% were positive for T790M. The overall rate of T790M positivity in the study cohort was 49.2%. LB performed before formal tumor progression according to Response Evaluation Criteria In Solid Tumors criteria was negative for T790M in all patients (n = 21; P = .012). T790M positivity was statistically significantly higher in cases of disease progression at extrathoracic metastatic sites (P = .008) and, specifically, in the case of worsening bone disease (P = .003).ConclusionOur study shows that the detection of T790M-positive patients whose disease progressed during treatment with first- and second-generation TKIs in real life was according to the literature. However, this result was obtained with a specific clinical course (repeat LBs and tissue rebiopsy), thus implying the necessity for multidisciplinary management. 相似文献
44.
目的探讨延续性4C护理对冠心病患者生存质量及再入院率的影响。方法选取2017年10月至2019年1月我院收治的冠心病患者78例,随机分为两组各39例。对照组采用常规护理,观察组采用延续性4C护理。护理4个月后,比较两组患者的生存质量及再入院率。结果护理4个月后,观察组的SF-36各维度评分均显著高于对照组,差异有统计学意义(P<0.05)。观察组的再入院率为5.13%,显著低于对照组的25.64%,差异有统计学意义(P<0.05)。结论冠心病患者采用延续性4C护理有利于改善出院后的生存质量,减少病情反复发作,降低再入院率。 相似文献
45.
46.
《Anaesthesia and Intensive Care Medicine》2020,21(11):548-557
Diabetes is a complex, chronic metabolic disorder affecting approximately 9.3% of the adult population with the estimated number of adults with diabetes worldwide having more than tripled since 2000. This increase has largely been attributed to global urbanization and lifestyle changes. Diabetes affects 10–15% of the surgical population. These patients are frequently elderly, have complex medical co-morbidities and present for both high-risk elective and emergency surgery. This multisystem disease poses a significant challenge to both anaesthesia and surgery with patients with diabetes demonstrating higher morbidity and mortality rates compared to their non-diabetic counterparts. It is crucial that good glycaemic control is maintained throughout the perioperative period as this has been shown to correlate with positive patient outcomes. It is well-recognized that a co-ordinated, multidisciplinary approach aimed at optimizing every point in the patient pathway from GP referral to post-discharge care is required to obtain the best outcomes for the surgical patient with diabetes. The anaesthetist has a key role in the perioperative diabetes multidisciplinary team. Patients themselves are well experienced in manging their own diabetes and should be involved in doing so whenever possible. 相似文献
47.
48.
Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types) 下载免费PDF全文
Maryum NoumanGhulam HaiderNeelma BukhariAveen YousufRabeea NoumanMehwish Roshan ShaikhShahid HussainBhunisha PavanRaja RahoolParas MemonSaima ZahoorKhalil MeharAbdus Sami 《Asian Pacific journal of cancer prevention》2020,21(3):825-830
Objective: To evaluate the response rate of Cisplatin plus Docetaxel in the treatment of locally advanced head and neck squamous cell carcinomas (HNSCC) at a tertiary care hospital in Karachi, Pakistan. Materials and Methods: It was a longitudinal study, conducted at the Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan from December 2018 to June 2019. One hundred patients of age 14-66 years of age of either gender with histologically proven Squamous Cell Carcinoma of Head and Neck, Stage III and IV (locally advanced) with no distant metastases were included in the study. Patients who were declared unresectable by the otolaryngologist and those with delayed appointment for radiation were given 3 cycles of Induction Chemotherapy with Cisplatin and Docetaxel, both at a dose of 75mg/m2 3 weekly. After 3 cycles, CT scan was repeated to assess the clinical response. Those patients who had partial or complete response as per RECIST criteria were re-assessed by the otolaryngologist and were planned for surgery if disease became resectable while other patients were referred for Concurrent Chemo-Radiation Therapy (CCRT). SPSS version 23 was used to analyze data. Results: The partial response was achieved in majority of the patients after Induction Chemotherapy with Docetaxel and Cisplatin (62%) with a complete response in 12 %. However, 22% showed progression of the disease, and 4% showed stable disease. The most frequent side effects observed were diarrhea (62%) and neutropenia (57%). Conclusion: Induction chemotherapy with Cisplatin and Docetaxel is a promising regimen with good response and favorable toxicity profile and can be considered as a potentially effective outpatient regimen for locally advanced squamous cell carcinoma of head and neck. 相似文献
49.
目的:研究对2型糖尿病患者实施延续护理的效果。方法:选取2018年1月~2018年12月在某院治疗后出院的2型糖尿病患者120例展开研究,按护理施差异分为两组,对照组常规护理,观察组在常规护理基础上实施延续护理,对比分析护理效果、护理后并发症发生率以及生活质量改善情况。结果:经护理后观察组血糖各指标均明显低于对照组(P<0.05);观察组发生率21.6%,对照组发生率41.6%(P<0.05);护理后观察组生活质量各项评分均明显高于对照组(P<0.05)。结论:对2型糖尿病患者实施延续护理效果显著,值得推广。 相似文献
50.
目的:探讨口服小剂量异维A酸联合外用2%超分子水杨酸治疗中重度痤疮的临床疗效。方法:共选取74例中重度痤疮患者作为研究对象,口服小剂量异维A酸10mg,1次/d。治疗组:37例,联合外用2%新型超分子水杨酸治疗;对照组:37例,联合外用夫西地酸乳膏及阿达帕林凝胶治疗。对两组患者治疗前后的皮损数量变化及治疗效果进行对比分析。结果:经过8周的治疗,两组研究对象的总皮损数量较治疗前均显著减少(P<0.05),且治疗组与对照组比较,无明显差异(P>0.05)。针对不同类型的皮损,治疗组对粉刺的疗效比对照组更具优势,对丘疹与结节的疗效无明显差异。结论:治疗中重度痤疮,小剂量异维A酸联合外用2%超分子水杨酸临床疗效较好,副作用小,可作为痤疮治疗的新选择。 相似文献